UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5359) 5359
life sciences & biomedicine (5083) 5083
humans (3739) 3739
male (3050) 3050
animals (2841) 2841
endocrinology & metabolism (2256) 2256
glucagon (1976) 1976
diabetes (1824) 1824
glucagon-like peptide 1 (1771) 1771
female (1758) 1758
diabetes mellitus, type 2 - drug therapy (1671) 1671
type 2 diabetes (1591) 1591
glucose (1463) 1463
peptides (1428) 1428
insulin (1399) 1399
middle aged (1146) 1146
rats (1122) 1122
hypoglycemic agents - therapeutic use (1106) 1106
blood glucose - metabolism (1069) 1069
adult (1061) 1061
mice (1017) 1017
glucagon-like peptide 1 - metabolism (912) 912
diabetes mellitus (900) 900
glucagon-like peptide-1 (883) 883
insulin - blood (877) 877
abridged index medicus (833) 833
pharmacology & pharmacy (793) 793
obesity (792) 792
glucagon-like peptide 1 - blood (787) 787
glp-1 (762) 762
glucagon-like peptide 1 - analogs & derivatives (754) 754
glucagon-like peptide-1 receptor (752) 752
insulin - metabolism (733) 733
hypoglycemic agents - administration & dosage (708) 708
liraglutide (701) 701
research (676) 676
dextrose (665) 665
rodents (661) 661
analysis (653) 653
diabetes mellitus, type 2 - blood (651) 651
digestive, oral, and skin physiology (646) 646
aged (634) 634
physiological aspects (619) 619
blood glucose - drug effects (587) 587
hypoglycemic agents - pharmacology (586) 586
insulin resistance (575) 575
glucagon-like peptide 1 - therapeutic use (573) 573
insulin secretion (545) 545
treatment outcome (540) 540
diabetes mellitus, type 2 - metabolism (532) 532
endocrine system (516) 516
glucagon-like peptide 1 - pharmacology (515) 515
health aspects (507) 507
physiology (501) 501
care and treatment (500) 500
glucagon-like peptide 1 - administration & dosage (497) 497
internal medicine (497) 497
medicine & public health (494) 494
peptides - pharmacology (488) 488
body weight (482) 482
hypoglycemic agents - adverse effects (473) 473
rats, sprague-dawley (466) 466
glucose metabolism (465) 465
hormones, hormone substitutes, and hormone antagonists (461) 461
mice, inbred c57bl (453) 453
nutrition & dietetics (443) 443
glucose tolerance test (437) 437
glucagon-like peptide-1 receptor - agonists (424) 424
metabolism (422) 422
hypoglycemic agents (414) 414
receptors, glucagon - agonists (413) 413
blood glucose - analysis (408) 408
peptides - therapeutic use (406) 406
glucagon - blood (404) 404
hormones (396) 396
exenatide (393) 393
dose-response relationship, drug (391) 391
drug therapy (391) 391
risk factors (385) 385
clinical trials (384) 384
diabetes therapy (378) 378
dipeptidyl-peptidase iv inhibitors - therapeutic use (369) 369
double-blind method (365) 365
hyperglycemia (350) 350
peptide fragments - pharmacology (350) 350
time factors (343) 343
peptides - administration & dosage (342) 342
proteins (334) 334
rats, wistar (330) 330
glucose - metabolism (327) 327
venoms - pharmacology (317) 317
biochemistry & molecular biology (316) 316
diet (309) 309
disease models, animal (307) 307
general & internal medicine (307) 307
neurosciences (305) 305
venoms - therapeutic use (304) 304
young adult (303) 303
body mass index (299) 299
receptors, glucagon - metabolism (298) 298
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6256) 6256
Japanese (37) 37
German (34) 34
French (15) 15
Chinese (9) 9
Portuguese (8) 8
Spanish (8) 8
Czech (7) 7
Danish (6) 6
Russian (3) 3
Swedish (3) 3
Polish (2) 2
Bosnian (1) 1
Dutch (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Psychopharmacology (Berlin, Germany), ISSN 1432-2072, 10/2018, Volume 236, Issue 2, pp. 603 - 611
Journal Article
Diabetes (New York, N.Y.), ISSN 1939-327X, 07/2009, Volume 58, Issue 10, pp. 2258 - 2266
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs... 
GLP‐1 analogue | type 2 diabetes | network meta‐analysis | systematic review | network meta-analysis | GLP-1 analogue | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes | Systematic review | Evidence-based medicine | Index Medicus
Journal Article